Teprotumumab for thyroid eye disease study
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests if the drug teprotumumab can help with symptoms of thyroid eye disease, such as bulging eyes, pain, or double vision. It is for adults who are beneficiaries of the Department of Defense (DOD).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a DOD beneficiary (such as active duty, retiree, or family member).
- You must be 18 years or older.
- You must have symptoms of thyroid eye disease like bulging eyes, eye pain, double vision, or eyelid swelling or redness.
- You must not have severe vision loss from pressure on the optic nerve that needs emergency surgery or radiation.
- You must not have uncontrolled diabetes or uncontrolled inflammatory bowel disease.
- You must not be pregnant or trying to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called teprotumumab for people with active thyroid eye disease. It is designed to help reduce eye bulging and other symptoms, and may be an option if you have not had strong treatments before.
This trial tests whether teprotumumab (a monoclonal antibody medication) works better than high-dose steroids after urgent eye socket surgery in patients with thyroid eye disease affecting the optic nerve. The goal is to prevent vision loss and improve eye symptoms.
This trial tests a new version of an antibody treatment (teprotumumab) for people with active thyroid eye disease. It aims to reduce bulging and inflammation of the eyes, and you must have had symptoms for less than 9 months to join.
This study compares two different treatment plans for Thyroid Eye Disease (TED): the standard 8 infusions of Tepezza versus a shorter 4-infusion course. It aims to see if 4 treatments might work just as well and be safer, but only for people who already respond well after the first 4 doses.
This trial tests a new drug called NTB003 for people with moderate-to-severe thyroid eye disease (TED). It aims to see if the drug can improve symptoms like eye bulging and double vision, and it may be an option for those whose disease is active or has been ongoing for a while.
This study tests whether tofacitinib, a new type of immune-modulating medication, can help people with moderate-to-severe thyroid eye disease (Graves' orbitopathy) whose eyes haven't improved with standard steroid treatments. The goal is to reduce eye swelling, bulging, and inflammation that affects daily life.
Hear when a new Graves Ophthalmopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.